Related Experiment Video
Updated: Dec 10, 2025
08:35
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
3.8K
Renal Denervation for Resistant Hypertension: Where Do We Stand?
Bo Liang1, Yu-Xiu Zhao2, Ning Gu3
1Nanjing University of Chinese Medicine, Nanjing, China.
Current Hypertension Reports
|September 4, 2020
Summary
Renal denervation (RDN) offers a promising minimally invasive option for resistant hypertension (RH). Further research is needed to refine RDN techniques and patient selection for optimal outcomes.
Area of Science:
- Cardiovascular Medicine
- Interventional Cardiology
- Nephrology
Background:
- Resistant hypertension (RH) poses a significant challenge in cardiovascular disease management.
- Renal sympathetic nerve activity plays a crucial role in the pathophysiology of hypertension.
Purpose of the Study:
- To review current data on renal denervation (RDN) for resistant hypertension.
- To offer practical guidance for establishing RDN services.
- To critically examine the evidence and identify future research directions.
Main Methods:
- Systematic review and critical analysis of existing research on RDN for RH.
- Evaluation of RDN technology, methods, and patient selection criteria.
Main Results:
- Renal denervation (RDN) selectively ablates renal sympathetic nerve fibers, potentially controlling blood pressure.
- Despite promising results, controversies and areas for improvement remain.
- Technological advancements and better patient stratification are key.
Conclusions:
- Renal denervation (RDN) is a novel, promising non-drug treatment for resistant hypertension (RH).
- Continuous innovation in RDN technology and methods is essential.
- Improved real-time success evaluation and patient selection will determine RDN's future feasibility in managing RH.
More Related Videos
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
737
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
737
01:25Antihypertensive Drugs: Direct Renin Inhibitors
1.1K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.1K
01:30Heart Failure V: Medical Management
125
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
125
01:22Heart Failure Drugs: Diuretics
674
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
674
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
2.0K
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
2.0K
01:29Hypertension II: Pathophysiology
541
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
541